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Abstract
DNA-reactive B cells play a central role in systemic lupus erythematosus (SLE); DNA antibodies precede clinical disease and
in established disease correlate with renal inflammation and contribute to dendritic cell activation and high levels of type 1
interferon. A number of central and peripheral B cell tolerance mechanisms designed to control the survival, differentiation
and activation of autoreactive B cells are thought to be disturbed in patients with SLE. The characterization of DNA-reactive
B cells has, however, been limited by their low frequency in peripheral blood. Using a tetrameric configuration of a peptide
mimetope of DNA bound by pathogenic anti-DNA antibodies, we can identify B cells producing potentially pathogenic
DNA-reactive antibodies. We, therefore, characterized the maturation and differentiation states of peptide, (ds) double
stranded DNA cross-reactive B cells in the peripheral blood of lupus patients and correlated these with clinical disease
activity. Flow cytometric analysis demonstrated a significantly higher frequency of tetramer-binding B cells in SLE patients
compared to healthy controls. We demonstrated the existence of a novel tolerance checkpoint at the transition of antigen-
naı ¨ve to antigen-experienced. We further demonstrate that patients with moderately active disease have more autoreactive
B cells in both the antigen-naı ¨ve and antigen-experienced compartments consistent with greater impairment in B cell
tolerance in both early and late checkpoints in these patients than in patients with quiescent disease. This methodology
enables us to gain insight into the development and fate of DNA-reactive B cells in individual patients with SLE and paves
the way ultimately to permit better and more customized therapies.
Citation: Jacobi AM, Zhang J, Mackay M, Aranow C, Diamond B (2009) Phenotypic Characterization of Autoreactive B Cells—Checkpoints of B Cell Tolerance in
Patients with Systemic Lupus Erythematosus. PLoS ONE 4(6): e5776. doi:10.1371/journal.pone.0005776
Editor: Wasif N. Khan, University of Miami, United States of America
Received February 25, 2009; Accepted April 16, 2009; Published June 2, 2009
Copyright:  2009 Jacobi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the NIH and the Irvington Institute Fellowship Program of the Cancer Research Institute. This work was supported by the
NIH and the Irvington Institute Fellowship Program of the Cancer Research Institute. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bdiamond@nshs.edu
Introduction
A wide variety of autoantibodies can be detected in patients
with systemic lupus erythematosus (SLE), a high percentage of
which bind to nuclear antigens [1] . Autoantibodies to dsDNA are
essentially diagnostic of the disease. They are considered to be
pathogenic as changes in their titer correlate with disease activity,
and in murine models they clearly contribute to lupus nephritis
[2]. Furthermore, they help induce an ‘‘interferon signature’’ that
results from activation of toll-like receptor (TLR) 9 in dendritic
cells by DNA-containing immune complexes [3] Moreover,
elevated titers of anti-DNA antibodies can be seen in patients
before the onset of clinical disease [4]. The mechanisms
underlying the failure to maintain tolerance that allow for
maturation and activation of autoreactive cells in SLE that are
specific for DNA remain incompletely understood. Murine models
have demonstrated the existence of multiple tolerance checkpoints
during B cell maturation and activation, both before and after the
germinal center response [5,6,7,8,9]. Defects in many of these
checkpoints have been reported in murine models of lupus; thus,
each appears necessary to stave off pathogenic autoreactivity
[10,11,12,13].
A significant percentage of the immature B cell repertoire is
autoreactive [14]. Negative selection of autoreactive B cells is
mediated by at least 3 processes: receptor editing, anergy
induction and deletion [15,16,17]. Autoreactive B cells that escape
early tolerance induction may mature to become marginal zone or
follicular cells depending on the nature of the interaction of the B
cell receptor (BCR) with antigen and the local microenvironment.
Thus, autoreactive B cells can exist as short-lived plasma cells or
germinal center-matured memory cells and long-lived plasma cells
[18,19]. In murine lupus models, autoreactive B cells are
phenotypically heterogeneous; genetic background, hormonal
milieu and antigen exposure all contribute to this diversity
[11,18,19,20,21,22]. These observations predict the presence of
extensive heterogeneity in patients with lupus.
Repertoire analysis of immature, transitional and naı ¨ve B cells
of patients with SLE and non-autoimmune individuals has
confirmed the presence of multiple tolerance checkpoints
[14,23,24,25]. An assessment of the percentage of self- or poly-
reactive B cells in early B cell populations has revealed two
tolerance checkpoints, one at the immature to transitional junction
and another one at the transitional to naı ¨ve junction. In a study of
a small number of lupus patients, it is clear that both of these
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5776tolerance checkpoints are incompletely maintained in SLE [25].
Peripheral tolerance in patients with lupus also appears
to be compromised. Autoreactive B cells expressing a VH4-34
encoded Ig heavy chain and possessing the 9G4 idiotype are
present in the mature B cell repertoire but are excluded from the
germinal center in non-autoimmune individuals; they can,
however, be readily found within tonsillar germinal centers in
SLE patients [26].
Our laboratory previously identified a peptide sequence
(DWEYS) that behaves as a dsDNA mimetope [27]. Antibodies
binding this sequence can cause renal disease and brain disease in
mice, and are detected frequently in serum of patients with SLE
and in cerebrospinal fluid of patients with neuropsychiatric
manifestations of SLE [28,29,30,31]. Immunization of BALB/c
mice with an octameric form of this peptide (DWEYS-MAP)
results in production of pathogenic IgG anti-dsDNA antibodies,
glomerular immunoglobulin deposition, proteinuria as well as
excitotoxic neuronal loss following a breach in the blood-brain
barrier [28,29,32].
A fluorochrome–labeled tetrameric DWEYS peptide (DWEYS-
tetramer), with a higher avidity for peptide reactive B cells than
monomeric peptide [33] was generated to identify the peptide/
dsDNA-cross-reactive B cell population in the murine immune
response. Using this reagent, we have previously identified peptide
dsDNA-cross-reactive B cells in mice immunized with DWEYS-
MAP [34,35]. Furthermore, we have shown that B cells in the
peripheral blood of lupus patients that bind the DWEYS-tetramer
are highly enriched for peptide and DNA reactivity [33].
This reagent therefore enables us to track the development and
fate of a subset of dsDNA-reactive B cells in individual patients
with SLE and gain insight into the heterogeneity of the anti-DNA
response. It additionally may facilitate the identification of clinical
subsets that may differ with respect to disease phenotype and
disease activity and in response to therapy. Our goal in this cross-
sectional study was to use the tetrameric DWEYS peptide to
evaluate the frequency of these autoreactive B cells in antigen-
naı ¨ve and antigen-experienced B cell subsets in SLE patients.
Methods
Phenotypic characterization of tetramer-binding B cells
by flow cytometry
Subject Population. Peripheral blood was drawn in tubes
containing citrate from 22 SLE patients fulfilling the revised ACR
criteria for SLE who attended the outpatient Rheumatology clinics
at Jacobi, Montefiore and Columbia University Medical Centers.
Theprotocol was approved bytheInstitutional ReviewBoards at all
three institutions. Informed consent was obtained from all patients
prior to enrollment. For study entry, all patients were required to be
18 years of age or older. Patients were excluded if they had known
infectionwithhepatitis B, hepatitis C or HIV. Patientswereassessed
for clinical disease activity using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI). Peripheral blood from a
control group consisting of 10 healthy subjects (4
Caucasian, 4 Asian, 1 African-American and 1 Hispanic)
was also analyzed. Peripheral blood from a control group
consisting of 10 healthy subjects was also analyzed. Peripheral blood
mononuclear cells (PBMCs) were prepared for flow cytometric
analysis using Ficoll Paque (GE Healthcare, Piscataway, NJ) density
gradient centrifugation and plasma of all individuals was stored at
220uC for assessment of anti-dsDNA and anti-DWEYS peptide
antibody levels.
DWEYSVWLSN-streptavidin-allophycocyanin tetramers were
generated incubating 25 ml biotinylated peptide (650 mM)
(AnaSpec, San Jose, CA) with 75 ml allophycocyanin-labeled
streptavidin (6.1 mM) (Molecular Probes, Eugene, OR) at 4uC
overnight. Subsequently, peptide–APC complexes were separated
from free peptide by gel filtration using a Bio-Gel P-30 spin
column (Bio Rad, Hercules, CA).
Immunofluorescence labeling for multicolor flow cytometric
analysis was performed by incubating PBMCs with anti-human
monoclonal antibodies to: CD3/CD14/CD16 (Pacific Blue,
UCHT-1/M5E2/3G8), CD19 (PerCP, SJ25C1), IgD (FITC,
IA6-2) (BD PharMingen, San Diego, CA), CD27 (PE, CBL27/
1), CD10 (FITC-labeled SJ5-1B4) (Invitrogen, Carlsbad, CA). In
addition, the tetramer was used to label DWEYS-peptide-specific
B lymphocytes. Labeling was performed in PBS/0.5%BSA/5 mM
EDTA at 4uC for 30 minutes. DAPI (49,6-diamidino-2-pheny-
lindole dihydrochloride, Molecular Probes) was added before flow
cytometric analysis (220 nM) to identify dead cells. Flow
cytometric analysis was performed using the LSRII (Becton
Dickinson, San Jose, CA) and FlowJo software (Treestar Inc,
Ashland, OR). Doublets were excluded from analysis. Up to
2.5610
6 events were acquired per analysis.
ELISAs. The ELISA assay for dsDNA-binding was performed
as described [29]. Briefly calf thymus dsDNA, 25 ml per well at 100
mg/ml, was adsorbed to 96-well half area plates (Corning Life
Science, Pittsburgh, PA), dried overnight at 37uC. DWEYS-
peptide at 20 mg/ml in PBS was adsorbed to Immulon 2HB
ELISA-plates (Thermo Electron Corporation, Waltham, MA)
plates at 4uC overnight. The following day, plates were blocked
with 2% BSA in PBS (dsDNA ELISA) or 3% FBS in PBS (peptide
ELISA) for 1 h at 37uC. Plasma was diluted 1:300 (dsDNA ELISA)
or 1:100 (peptide ELISA) in PBS before incubating plates for 1 h
at 37uC. All ELISAs were developed with alkaline phosphatase
conjugated goat anti-human IgG (Southern Biotechnology) and
OD405 was measured using a Victor microplate reader (Perkin
Elmer, Waltham, MA).
Statistical analysis. Frequencies of B cell subpopulations
were calculated using FlowJo software (TreeStar). Differences in
frequencies of tetramer-binding B cells between SLE patients and
healthy controls and in different B cell subsets between patients
grouped according to disease activity were determined using the
unpaired, t tests. The Spearman’s rank test was used to analyze if
there was a correlation between the IgG anti-dsDNA-antibody
and anti-DWEYS-antibody levels and the Mann Whitney U test to
compare serological results of patients and normal individuals.
The paired or unpaired t test as well as ANOVA were used to
compare frequencies of tetramer-binding B cells within different B
cell subsets. P values,0.05 were considered to be statistically
significant. Data was analyzed using the GraphPad Prism4-
(GraphPad, San Diego, CA).
Results
Tetramer-binding B cells in peripheral blood of lupus
patients
To determine the frequency of tetramer-binding B cells,
peripheral blood cells of 22 patients with SLE (20 female, 2
male, 35.8610.7 years old) and 10 healthy donors (8 female, 2
male, 32.267.9 years old) were analyzed by flow cytometry. The
characteristics of the patient cohort are shown in Table 1. Both
IgG anti-peptide antibody levels and IgG anti-dsDNA antibody
levels determined by ELISA were significantly higher in SLE
patients compared to healthy subjects (p,0.004, Figure 1A and
p,0.0001, Figure 1B). Using routine clinical assays, 15 patients
had elevated levels of anti-dsDNA antibodies (Table 1). Eleven
patients had elevated anti-peptide antibody levels (at least 2SD
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analyzed, a significant correlation between IgG anti-dsDNA and
anti-peptide antibody levels was identified, (rs=0.53, p=0.002)
although some patients exhibited a discordance between anti-
DNA and anti-peptide reactivity.
Flow cytometric analysis of peripheral blood cells performed
concurrently using the gating strategy shown in Figure 2A
demonstrated that all groups differed significantly
(one way ANOVA p,0.002) a higher frequency of tetramer-
binding B cells was present in SLE patients compared to healthy
donors (0.08560.065% vs. 0.03860.010%, p,0.04, Figure 2B).
Patients with moderately active disease (SLEDAI.4) had a
significantly higher frequency of tetramer-binding B cells than
patients with quiescent disease (SLEDAI#4) (0.13460.091% vs.
0.06160.031%, p,0.02). However, even patients with inactive
disease had a significantly elevated frequency of tetramer-binding
B cells compared to healthy donors (p,0.04).
Phenotype of tetramer-binding B cells in the peripheral
blood of lupus patients
We are particularly interested in the regulation of B cells that
have encountered antigen, as the checkpoints that are operative
after antigen activation are less well studied. We, therefore,
performed a detailed analysis of B cell subsets to determine the
frequency of tetramer-binding B cells in antigen-inexperienced
(CD27
2IgD
+), or antigen-experienced subsets including
IgD
+CD27
+ and Ig-class-switched (IgD
2CD27
+) memory cell
subsets and plasmablasts (CD27
++CD19
low) in individual patients
with SLE. Since the CD27
2IgD
2 cell subset, which appears to be
enhanced in the peripheral blood of patients with SLE [36,37]
Table 1. Patient characteristics
disease manifestations therapeutic regimen ELISA
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J4 42 F A 2 x x n
J6 31 F H 4 x x x x n
J9 34 M A 2 x x p
J24 40 F H 4 x x p
C36 39 F H 0 5 x n
J1 23 F H 16 x x x x 80 x p
J21 41 F A 2 n.d. 15 x p
J34 44 F A 4 x x x p
J50 24 F H 6 x x x x p
J57 22 F H 12 x x x x x p
J59 23 F H 20 x x x 5 p
C34 42 M H 2 20 x p
C35 29 F H 4 x n.d. 20 x x p
J7 32 F A 0 5 x n
J52 35 F A 1 x x n
J60 57 F A 16 x x 20 x p
J62 29 F A 4 x x p
J63 43 F A 4 x 20 n
C14 22 F H 8 x x 15 x p
C30 33 F H 2 2.5 x p
C31 41 F A 6 x x 25 x x p
C42 62 F A 2 x n
*HCQ=hydroxychloroquin.
{MMP=mycophenolate Mofetil.
n.d.=not determined.
#active nephritis (nephritic sediment or proteinuria (.0.5 g/day).
A=African-American,H=Hispanic.
doi:10.1371/journal.pone.0005776.t001
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simply by exposure to TLR-ligands or cytokines such as IL-10 or
IL-21 or BAFF [38,39,40,41], this subset was considered to be
heterogeneous. It probably includes both, antigen-naive and
antigen-experienced B cells, and was therefore excluded from
final analyses. This analysis was performed for SLE
patients only as the frequencies were too low in control
individuals to distinguish signal from background in
most subpopulations. The gating strategy for these analyses is
depicted in Figure 3.
The frequency of tetramer-binding cells was greater in both the
antigen-naı ¨ve and the antigen-experienced subsets in patients with
moderately active disease (n=7) than in patients with quiescent
disease (n=15) (p,0.025 and p,0.005, respectively) (Figure 4 A
and B). Interestingly, we observed a lower frequency of tetramer-
binding B cells in the antigen-experienced population than in
antigen-naı ¨ve population in both patients with quiescent disease
and patients with moderately active disease (p,0.004 and
p,0.013, respectively), demonstrating that there is a partial,
although inadequate, maintenance of tolerance checkpoints after
antigen activation even in active lupus patients (Figure 4 A and
B). Indeed, every patient exhibited a decrease in frequency of
tetramer-binding B cells in the antigen-experienced population
compared to the antigen-naı ¨ve population.
Interestingly, when we analyzed total number of tetramer-
binding B cells with an antigen-experienced phenotype we found
that patients with active disease had significantly higher numbers
compared to patients with quiescent disease (p,0.025). In
contrast, we observed no difference in the total number of
tetramer-binding naı ¨ve B cells in the two patient groups (Figure 4C
and D). This analysis may, however, be distorted by one patient
with inactive disease and high numbers of naı ¨ve tetramer-binding
B cells. If this one patient was excluded this difference became
statistically significant as well (p,0.02).
Figure 1. Antibody titters. A significant difference exists between the IgG anti-peptide (A) and anti-dsDNA (B) antibody levels in plasma samples
of patients with SLE and healthy controls (Mann Whitney U-test, mean values are depicted). C. A significant correlation exists between anti-peptide
IgG and anti-dsDNA IgG levels in all individuals analyzed. Healthy controls are shown in green, lupus patients in black (Spearman’s rank correlation
test).
doi:10.1371/journal.pone.0005776.g001
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was related to total B cell number. We reasoned that B cell
lymphopenia might lead to increased BAFF levels and impaired
negative selection. Contrary to our expectation, there was no
relationship between total B cell number and frequency of
tetramer-binding B cells (Figure 4E), although there was a
relationship between total B cell number and the frequency of
tetramer-binding B cells in antigen-experienced subsets (rS=0.56,
p,0.01,Figure 4F).
To analyze whether differencesinethnicitymightassociatewith
differences in B cell regulation Hispanic (n=11) and African
American (n=11) patients were compared. No significant
difference was observed between these ethnic groups with respect
to frequency of tetramer-binding B cells within both the antigen-
naive and the antigen-experienced subsets. With only 2 African-
American patients with moderately active disease, it was not
possible to ascertain the impact of ethnicity on the tolerance
checkpoint at the antigen-to-antigen-naı ¨ve experienced junction.
We also studied the transitional to naı ¨ve B cell checkpoint in a
subset of patients (n=4 with quiescent disease and n=3 with
moderately active disease). In each patient, there was again a
reductionintetramer-bindingBcellsastheB cellsmatured fromthe
transitional compartment to the naı ¨ve compartment (Figure 5).
Although the number of individuals was limited, these differences
almost reached statistical significance for patients with quiescent
disease (p=0.058) and for patients with moderately active disease
(p=0.05). Interestingly, while the frequency of tetramer-binding B
cells was comparable in the transitional population for both patients
with quiescent disease and patients with moderately active disease
(0.3660.13% vs. 0.4260.24%, respectively), patients with moder-
ately active disease exhibited a significantly higher frequency of
tetramer-binding B cells in the naı ¨ve population (0.1560.05% vs.
Figure 3. Gating strategy used to characterize tetramer-binding B cells further. In addition to the gating procedure depicted in Figure 2A,
tetramer-binding and tetramer-negative B cells were subdivided in CD27
+ memory B cells and CD27
++ plasmablasts (antigen-experienced) and
CD27
2IgD
+ antigen-inexperienced B cells, comprising both transitional (CD10
+) and naı ¨ve (CD10
2) B cells.
doi:10.1371/journal.pone.0005776.g003
Figure 2. Tetramer-binding B cells. A: Gating strategy. PBMCs were incubated with monoclonal antibodies to human: CD3/CD14/CD16 and
CD19. In addition, the tetramer was used to label DWEYS-peptide-specific B lymphocytes. DAPI was added before flow cytometric analysis to identify
dead cells. Doublets were excluded from analysis. After gating out dead cells, doublets and CD3, CD14- or CD16-positive cells, B cells (CD19-positive
cells) were gated and the frequency of tetramer-binding B cells was determined as shown in a patient with SLE and a healthy control (HC). B: Patients
with SLE exhibit a significantly higher frequency of tetramer-binding B cells compared to healthy controls and active patients a significantly higher
frequency of tetramer-binding B cells than inactive patients. (unpaired t test. Mean values are depicted). HC=healthy controls
doi:10.1371/journal.pone.0005776.g002
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checkpoint in patients with moderately active disease.
Discussion
The mechanisms underlying the failure of B cell tolerance as
well as the contribution of different B cell subsets to the
pathogenesis of SLE remain incompletely understood and the
degree of heterogeneity in these parameters among lupus patients
has not been extensively investigated. This study employed a
tetrameric fluorochrome-labeled form of a dsDNA mimetope to
characterize dsDNA-specific B cells obtained from the peripheral
blood of patients with SLE. The tetramer was previously
successfully used to track the peptide-specific B cell population
in peptide-immunized BALB/c mice [33,34]. Using the same tool,
we were recently able to identify and enrich a rare peptide-specific
B cell population in patients with SLE, and to demonstrate that
the antibodies derived from these B cells bound peptide and were
largely cross-reactive to dsDNA [35]. We now show that this cross-
reactive tetrameric peptide can be used to investigate tolerance
checkpoints in SLE patients. We noted that all lupus patients had a
higher frequency of tetramer-binding B cells than did healthy
controls.
A characterization of these tetramer-binding B cells confirmed
the anticipated heterogeneity of patients with SLE. Most tetramer-
binding B cells were antigen-naı ¨ve (70%), consistent with a
previous study showing that lupus patients can have a high
frequency of ANA-reactive B cells in the antigen-naı ¨ve B cell
subsets even when in clinical remission or serologically inactive
[25]. We identified a checkpoint for maintaining B cell tolerance
that occurs during or after antigenic encounter. This checkpoint at
the transition of autoreactive B cells from an antigen-naı ¨ve to an
antigen-experienced compartment was present in lupus patients
whether quiescent or moderately active. There was also a
diminution of tetramer-binding B cells in lupus patients as B cells
progressed from the transitional subset to the naı ¨ve subset
although this was studied in a smaller number of patients.
Interestingly, this checkpoint was more compromised in those
patients with moderately active disease. It seems probable that
multiple checkpoints are each partially compromised in lupus
patients. Whether these checkpoints utilize similar or distinct
mechanisms to tolerize autoreactive B cells, remains to be
determined.
It has been reported that more active patients display high
serum levels of BAFF [42]. We believe this may account for the
greater impairment in the early transitional to naı ¨ve B cells
checkpoint present in patients with moderately active disease. In
mice, elevated BAFF levels permit the survival of autoreactive
transitional B cells that would normally not mature to become
naı ¨ve, immunocompetent B cells [43]. The increased BAFF levels
in active patients may reflect increased BAFF production by
dendritic cells exposed to nucleic acid-containing immune
complexes, or could be related to disease-associated or therapy-
associated B cell lymphopenia in both patients with active and
patients with quiescent disease.
The decreased expression of FccRIIb on memory B cells or
immediate plasma cell precursors which occurs in approximately
50% of SLE patients may be one mechanism which contributes
uniquely to the observed diminished tolerance in antigen-
experienced B cells as FccRIIb inhibits the B cell response in
post-germinal center compartments and regulates plasma cell
homeostasis [44,45,46,47]. Classical mechanisms of B cell
tolerance that have been demonstrated in the mouse such as
follicular exclusion might also be impaired in patients with SLE
due to lower FccRIIb expression [48] or due to diminished
competition from a non-autoreactive B cell population [49]. It is
not clear if B cell lymphopenia, characterized by increased BAFF
expression, affects late tolerance checkpoints as well.
It is necessary to note that patients in this study were on a
variety of medications (Table 1). Whether these also contributed to
aspects of the B cell repertoire cannot be assessed as the
medication regimens in our patient cohort were too varied.
Additional studies of patients selected for medication use will be
needed to address this question.
Overall, lupus patients in this study displayed an increased
frequency of autoreactive B cells in the early and late B cell
repertoire independent of disease activity. Furthermore, an
impairment of early selection checkpoints was associated with a
greater disease activity and a significantly higher frequency of
autoreactive B cells in the antigen-experienced B cell subsets.
Given the phenotypic diversity of anti-DNA reactive B cells and
the diverse tolerance mechanisms that are abrogated in murine
models of SLE, the methodology we have used will be informative
in longitudinal studies to track the changes in frequency and
phenotype of autoreactive cells as individual patients progress from
clinically quiescent disease to flare and back to quiescence. The
methodology allows for an analysis of the representation of
autoreactive B cells in different B cell subsets in a far larger
number of patients than can be examining in methodologies that
rely on cloning antibodies and expressing from individual B cells.
Determining which mechanisms operate early in selection and
which operate following antigen-activation, and which of these are
impaired in SLE promises to be an important guide to identify
immunologically distinct patient cohorts and to improve and
customize therapeutic strategies.
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Figure 4. Late checkpoints of B cell tolerance. A significant difference exists between the frequency of tetramer-binding B cells within the
antigen-inexperienced (naı ¨ve and transitional) B cell subsets and the antigen-experienced B cell subsets in patients with quiescent disease (A) and
patients with active disease (B) (paired t test, mean values are depicted). The frequency of tetramer-binding cells was greater in both the antigen-
naı ¨ve and the antigen-experienced subsets in patients with moderately active disease (n=7) than in patients with quiescent disease (n=15)
(#p,0.025 and *p,0.005, respectively, unpaired t test). (C) The total number of tetramer-binding B cells in antigen-experienced subsets
was greater in patients with active disease than in patients with quiescent disease (p,0.025, unpaired t test). (D) the, total number
of tetramer-binding B cells in the antigen-naı ¨ve subsets was not different between the two patient groups. (E) The total B cell
number and frequency of tetramer-binding B cells were not significantly correlated although there was a relationship between
total B cell number and the frequency of tetramer-binding B cells in antigen-experienced subsets (rS=0.56, p,0.01, Spearman’s
rank correlation test) (F).
doi:10.1371/journal.pone.0005776.g004
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5776Figure 5. Early checkpoints of B cell tolerance. Phenotype of tetramer-binding B cells in 7 patients with SLE in patients with quiescent disease,
defined as a SLEDAI#4( A) or patients showing signs of clinical disease activity, defined as a SLEDAI.4( B). The percentage of tetramer-binding and
tetramer-negative B cells with a transitional phenotype (bordeaux) and the calculated percentage of tetramer-binding (T+) and tetramer-negative (T-)
B cells with a naı ¨ve phenotype (yellow) in 7 patients with SLE. The percentage of naı ¨ve B cells was calculated by subtracting the percentage of
CD27
2CD10
+ B cells from the percentage of CD27
2IgD
+ B cells. The percentage of tetramer-binding and tetramer-negative B cells with an antigen-
experienced phenotype comprising CD27
+ switched (IgD
2) and non-switched (IgD
+) memory B cells and CD19
lowCD27
++ plasmablasts is shown in
blue. CD27
2IgD
2 B cells (grey) were excluded from analysis. The right panel of the figure shows the frequencies of tetramer-binding B cells within the
transitional and naı ¨ve B cell subsets in these lupus patients. Mean values are shown. *Patients with moderately active disease exhibited a significantly
higher frequency of tetramer-binding B cells in the naı ¨ve population (p,0.02, unpaired t test).
doi:10.1371/journal.pone.0005776.g005
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